{"name":"Zhiyong Yu","slug":"zhiyong-yu","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiaEFVX3lxTFBUTW9pNlFsanBhVDBYMTBnT29TWjFERlZ1cWlRLUtZVzQ2X1FkUkNXdmF2bGI2VzBOclByR21JS1dEY25IeFBWVE5HTnBURjFXTkFTcHJDYmFSelJDOExIR0hGR1ZMbktv?oc=5","date":"2024-09-20","type":"pipeline","source":"Wiley Online Library","summary":"SCR-7952, a highly selective MAT2A inhibitor, demonstrates synergistic antitumor activities in combination with the S -adenosylmethionine-competitive or the methylthioadenosine-cooperative protein arg","headline":"SCR-7952, a highly selective MAT2A inhibitor, demonstrates synergistic antitumor activities in combination with the S -a","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}